- ADMA reported their Q2 earnings that revealed a 129% increase year-over-year in revenues. In addition, the company reduced their net loss, while improving gross margins.
- ADMA expects to pull in $100M or more in revenue during 2021 and is sticking to their plans to expand their plasma collection network despite the pandemic.
- Management expects the company to pull in around $300M or more and be profitable beginning no later than the first quarter of 2024.
- ADMA continues to trade at a significant discount compared to its peers. I believe that the pandemic is weighing the ticker down and could be a lingering threat for an extended period of time.
- I am feeling extremely bullish about ADMA’s long-term upside and will continue accumulating shares on dips in the share price.
For further details see:
ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report